INSMED's Losses Widen Amid Soaring R&D, BRINSUPRI Launch Boosts Revenue

Ticker: INSM · Form: 10-Q · Filed: 2025-10-30T00:00:00.000Z

Sentiment: mixed

Topics: Biopharmaceutical, Drug Development, Revenue Growth, Net Loss, R&D Expenses, Commercialization, Cash Burn

Related Tickers: INSM

TL;DR

**INSMED is burning cash fast to launch BRINSUPRI and fund its pipeline, so expect continued losses despite strong revenue growth.**

AI Summary

INSMED Inc. reported a net loss of $370.0 million for the three months ended September 30, 2025, an increase from $220.5 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss widened to $948.3 million from $678.2 million in the prior year. Product revenues, however, saw significant growth, reaching $142.3 million for the quarter, up from $93.4 million in Q3 2024, and $342.6 million for the nine months, compared to $259.3 million in 2024. This revenue increase was driven by the continued commercialization of ARIKAYCE and the recent FDA approval of BRINSUPRI on August 12, 2025. Operating expenses surged to $508.3 million for the quarter, primarily due to a substantial increase in research and development (R&D) to $186.4 million and selling, general and administrative (SG&A) expenses to $186.4 million, reflecting investments in pipeline and commercialization efforts. The change in fair value of deferred and contingent consideration liabilities also significantly impacted operating expenses, rising to $104.7 million for the quarter. The company maintains $334.8 million in cash and cash equivalents and $1,345.2 million in marketable securities as of September 30, 2025, but anticipates substantial future cash requirements to fund its R&D and commercialization activities.

Why It Matters

INSMED's expanding net loss, despite robust revenue growth, signals aggressive investment in its pipeline and commercialization, particularly with the recent FDA approval of BRINSUPRI. For investors, this indicates a long-term growth strategy focused on market penetration and new drug development, but also highlights increased cash burn and potential dilution risks. Employees may see continued job security and growth opportunities within R&D and commercial teams. Customers, especially those with non-cystic fibrosis bronchiectasis, benefit from a new treatment option, BRINSUPRI, potentially improving patient outcomes and expanding market access. The broader market will watch how INSMED balances its significant R&D expenditures with commercial success in competitive therapeutic areas like NTM lung disease and bronchiectasis.

Risk Assessment

Risk Level: high — INSMED reported a net loss of $948.3 million for the nine months ended September 30, 2025, a significant increase from $678.2 million in the prior year, indicating a substantial and growing cash burn. The company's cash and cash equivalents decreased from $555.0 million at December 31, 2024, to $334.8 million at September 30, 2025, reflecting heavy operating and investing activities. Furthermore, the 'Change in fair value of deferred and contingent consideration liabilities' surged to $181.9 million for the nine months, introducing volatility and uncertainty to future financial performance.

Analyst Insight

Investors should closely monitor INSMED's BRINSUPRI sales trajectory and ARIKAYCE's sustained performance to justify the escalating R&D and SG&A expenses. Consider the company's ability to manage its cash burn and potential need for future capital raises, which could dilute existing shareholders.

Financial Highlights

debt To Equity
1.50
revenue
$142.3M
operating Margin
-257.0%
total Assets
$2,360.7M
total Debt
$703.6M
net Income
-$370.0M
eps
N/A
gross Margin
79.4%
cash Position
$334.8M
revenue Growth
+52.4%

Revenue Breakdown

SegmentRevenueGrowth
ARIKAYCE$142.3M+52.4%
BRINSUPRIN/AN/A

Key Numbers

Key Players & Entities

FAQ

What were INSMED's product revenues for the three months ended September 30, 2025?

INSMED's product revenues, net, for the three months ended September 30, 2025, were $142,342 thousand, a significant increase from $93,425 thousand reported in the same period of 2024.

How much was INSMED's net loss for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, INSMED reported a net loss of $948,290 thousand, which is a substantial increase compared to the $678,224 thousand net loss for the nine months ended September 30, 2024.

What was the primary driver of increased operating expenses for INSMED in Q3 2025?

The primary drivers of increased operating expenses for INSMED in Q3 2025 were research and development expenses, which rose to $186,415 thousand from $150,809 thousand, and selling, general and administrative expenses, which increased to $186,376 thousand from $118,930 thousand.

When did INSMED receive FDA approval for BRINSUPRI?

INSMED received US Food and Drug Administration (FDA) approval for BRINSUPRI (brensocatib 25 mg and 10 mg tablets) on August 12, 2025, for the treatment of non-cystic fibrosis bronchiectasis in adults and children 12 years and older.

What is INSMED's cash and cash equivalents position as of September 30, 2025?

As of September 30, 2025, INSMED had $334,764 thousand in cash and cash equivalents, a decrease from $555,030 thousand at December 31, 2024.

What are the key risks highlighted in INSMED's 10-Q filing regarding future funding?

INSMED expects its future cash requirements to be substantial and may need to raise additional capital to fund operations, clinical trials, and commercialization efforts. Failure to obtain sufficient additional funds could force the company to delay, restrict, or eliminate development programs or commercialization efforts.

How has INSMED's common stock outstanding changed?

INSMED's common stock outstanding increased to 212,583,015 shares as of September 30, 2025, from 179,382,635 shares at December 31, 2024, indicating an increase of over 33 million shares.

What is ARIKAYCE approved for in the United States?

ARIKAYCE is approved in the United States as ARIKAYCE (amikacin liposome inhalation suspension) for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting.

What is the significance of the 'Change in fair value of deferred and contingent consideration liabilities' for INSMED?

The 'Change in fair value of deferred and contingent consideration liabilities' significantly impacted INSMED's operating expenses, increasing to $181,953 thousand for the nine months ended September 30, 2025, from $106,482 thousand in the prior year, reflecting potential future payment obligations related to acquisitions.

Does INSMED have significant customer concentration?

Yes, INSMED has significant customer concentration, with Customer A representing 30%, Customer B 26%, and Customer C 21% of gross product revenue for the nine months ended September 30, 2025. This means a large portion of their revenue comes from a few key customers.

Risk Factors

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Insmed focus on developing novel therapies for rare and serious diseases, often requiring substantial investment in clinical trials and commercialization. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, with success often depending on innovation, intellectual property, and effective market access.

Regulatory Implications

Insmed operates in a highly regulated environment. The FDA approval of BRINSUPRI is a significant milestone, but ongoing compliance with manufacturing standards, post-market surveillance, and potential future regulatory reviews for pipeline assets are critical. Delays or failures in regulatory processes can severely impact product timelines and financial performance.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]
  5. [object Object]

Key Dates

Glossary

ARIKAYCE
Insmed's first commercial product, an inhaled amikacin liposome suspension approved for Mycobacterium avium complex (MAC) lung disease. (Primary driver of current product revenues.)
BRINSUPRI
Insmed's second commercial product, an oral treatment for non-cystic fibrosis bronchiectasis (NCFB), approved on August 12, 2025. (Represents a significant new revenue opportunity and pipeline expansion.)
MAC lung disease
A rare and often chronic infection caused by Mycobacterium avium complex, which can lead to irreversible lung damage and be fatal. (The indication for which ARIKAYCE received its initial approvals.)
NCFB
Non-cystic fibrosis bronchiectasis, a chronic lung disease for which BRINSUPRI is approved. (The indication for Insmed's second commercial product.)
DPP1 inhibitor
Dipeptidyl peptidase 1 inhibitor, a class of drugs that can reduce neutrophil inflammation, relevant to diseases like bronchiectasis. (Mechanism of action for BRINSUPRI.)
Contingent consideration
Future payments owed to sellers in an acquisition, contingent upon the achievement of certain milestones or performance targets. (Significant impact on operating expenses and net loss due to changes in fair value.)
Accumulated deficit
The cumulative net losses of a company since its inception, representing the total losses that have not been offset by profits. (Indicates the company's historical unprofitability, with a current deficit of $5,308.2 million.)
Marketable securities
Investments in stocks, bonds, or other financial instruments that can be readily bought or sold in the open market. (Provides significant liquidity for the company, with holdings of $1,345.2 million.)

Year-Over-Year Comparison

Compared to the prior year, Insmed has demonstrated strong revenue growth, with product revenues increasing by 52.4% in Q3 2025 to $142.3M, driven by ARIKAYCE and the new BRINSUPRI launch. However, this growth has been overshadowed by a significant increase in operating expenses, leading to a widened net loss of $370.0M for the quarter. The company's cash position has decreased from $555.0M to $334.8M, while marketable securities have increased, providing liquidity. New risks related to the substantial increase in contingent consideration liabilities and potential share dilution have emerged.

Filing Stats: 4,483 words · 18 min read · ~15 pages · Grade level 19.5 · Accepted 2025-10-30 07:00:48

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION ITEM 1 Consolidated Financial Statements Consolidated Balance Sheet s as of September 30, 2025 (unaudited) and December 31, 2024 3 Consolidated Statements of Comprehensive Loss (unaudited) for the three and nine months ended September 30, 2025 and 2024 4 Consolidated Statements of Shareholders' Equity (unaudited) for the three and nine months ended September 30, 2025 and 2024 5 Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2025 and 2024 7

Notes to Consolidated Financial Statements (unaudited)

Notes to Consolidated Financial Statements (unaudited) 8 ITEM 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 29 ITEM 3

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 47 ITEM 4

Controls and Procedures

Controls and Procedures 48

OTHER INFORMATION

PART II. OTHER INFORMATION ITEM 1

Legal Proceedings

Legal Proceedings 48 ITEM 1A

Risk Factors

Risk Factors 48 ITEM 2 Unregistered Sales of Equity Securities and Use of Proceeds 53 ITEM 5 Other Information 53 ITEM 6 Exhibits 54 SIGNATURE 55 Unless the context otherwise indicates, references in this Form 10-Q to "Insmed Incorporated" refers to Insmed Incorporated, a Virginia corporation, and the "Company," "Insmed," "we," "us" and "our" refer to Insmed Incorporated together with its consolidated subsidiaries. INSMED, PULMOVANCE, ARIKAYCE, and BRINSUPRI are trademarks of Insmed Incorporated. This Form 10-Q also contains trademarks of third parties. Each trademark of another company appearing in this Form 10-Q is the property of its owner. 2

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS INSMED INCORPORATED Consolidated Balance Sheets (in thousands, except par value and share data) As of As of September 30, 2025 December 31, 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 334,764 $ 555,030 Marketable securities 1,345,222 878,796 Accounts receivable 65,259 52,012 Inventory 120,965 98,578 Prepaid expenses and other current assets 65,597 37,245 Total current assets 1,931,807 1,621,661 Fixed assets, net 89,671 80,052 Finance lease right-of-use assets 16,239 18,273 Operating lease right-of-use assets 10,708 17,257 Intangibles, net 84,588 58,652 Goodwill 136,110 136,110 Other assets 91,613 93,226 Total assets $ 2,360,736 $ 2,025,231 Liabilities and shareholders' equity Current liabilities: Accounts payable and accrued liabilities $ 409,835 $ 285,209 Finance lease liabilities 3,246 2,961 Operating lease liabilities 4,133 9,358 Total current liabilities 417,214 297,528 Debt, long-term 539,719 1,103,382 Royalty financing agreement 163,854 161,067 Contingent consideration 259,600 144,200 Finance lease liabilities, long-term 21,595 24,064 Operating lease liabilities, long-term 7,588 9,112 Other long-term liabilities 5,595 499 Total liabilities 1,415,165 1,739,852 Shareholders' equity: Common stock, $ 0.01 par value; 500,000,000 authorized shares, 212,583,015 and 179,382,635 issued and outstanding shares at September 30, 2025 and December 31, 2024, respectively 2,126 1,794 Additional paid-in capital 6,249,654 4,645,791 Accumulated deficit ( 5,308,207 ) ( 4,359,917 ) Accumulated other comprehensive gain (loss) 1,998 ( 2,289 ) Total shareholders' equity 945,571 285,379 Total liabilities and shareholders' equity $ 2,360,736 $ 2,025,231 See accompanying notes to the unaudited consolidated financial statements 3 INSMED INCORPORATED Consolidated Statements of Comprehensive Loss (unaudited) (in thousands, except per share data) Three Months Ended Sep

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 1. The Company and Basis of Presentation Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company's first commercial product, ARIKAYCE, is approved in the United States (US) as ARIKAYCE (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis (CF). In March 2021, Japan's Ministry of Health, Labour and Welfare (MHLW) approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. NTM lung disease caused by MAC (which the Company refers to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. The Company's second commercial product, BRINSUPRI (brensocatib 25 mg and 10 mg tablets), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (referred to as bronchiectasis or NCFB) in adults and children 12 years and older, received US Food and Drug Administration (FDA) approval on August 12, 2025. Brensocatib is a small molecule, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), that the Company is also developing for the treatment of patients with chronic rhinosinusitis without nasal polyps (CRSsNP) and

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) 1. The Company and Basis of Presentation (Continued) source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company's commercial, regulatory and development activities. Any future financing will also be contingent upon market conditions. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiarie s, Celtrix Pharmaceuticals, Inc., Insmed France SAS, Insmed Gene Therapy LLC, Insmed Germany GmbH, Insmed Godo Kaisha, Insmed Holdings Limited, Insmed Innovation UK Limited, Insmed Ireland Limited, Insmed Italy S.R.L., Insmed Limited, Insmed Netherlands B.V., Insmed Netherlands Holdings B.V., and Insmed Switzerland GmbH. 2. Summary of Significant Accounting Policies The Company's complete listing of significant accounting policies is set forth in Note 2 of the notes to the consolidated financial statements in the Company's Annual Report on Form 10-K for the year ended December 31, 202 4 . Selected significant accounting policies are discussed in detail below. Use of Estimates —The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, sto

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) 2. Summary of Significant Accounting Policies (Continued) Impairment Assessment —The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing the carrying value of the assets to the fair value of the assets. Business Combinations and Asset Acquisitions —The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabili

View on Read The Filing